Advertisement

Recurrence in NMIBC

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala
Chapter

Abstract

European Association of Urology (EAU) guidelines recommend a follow-up transurethral resection of bladder tumors (reTUR-B) for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) 2–6 weeks after the initial resection (Merseburger et al. in Curr Opin Urol 18(5):513–518, 2008). This chapter covers recurrence in NMIBC

References

  1. Busato Júnior WF, Almeida GL, Ribas CA, Ribas Filho JM, De Cobelli O. EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice? Clin Genitourin Cancer. 2016;14(2):176–82.CrossRefGoogle Scholar
  2. Hartinger J, Häußermann R, Olbert P, Hofmann R, Hegele A. Predictors for presence of residual tumor in follow-up transurethral resection of bladder tumors: single center results. Urologe A. 2013;52(4):557–61.CrossRefGoogle Scholar
  3. Luján S, Santamaría C, Pontones JL, Ruiz-Cerdá JL, Trassierra M, Vera-Donoso CD, Solsona E, Jiménez-Cruz F. Risk estimation of multiple recurrence and progression of non muscle invasive bladder carcinoma using new mathematical models. Actas Urol Esp. 2014;38(10):647–54.CrossRefGoogle Scholar
  4. Merseburger AS, Matuschek I, Kuczyk MA. Bladder preserving strategies for muscle-invasive bladder cancer. Curr Opin Urol. 2008;18(5):513–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations